stockrow
Friday 6 November 2026
Export NAMS’s income statement to Excel — free account
NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
19.09
0.20
+1.06%
Follow NAMS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
184.61 | 172.66 | 587.14 | 116.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(101.63) | (127.31) | (106.62) | (75.91) | |
P/B ratio |
6.08 | 5.86 | 6.62 | 4.79 | |
Price to Tangible BV |
6.08 | 5.86 | 6.63 | 4.79 | |
EV/Sales |
156.28 | 144.41 | 497.94 | 91.91 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(23.80) | (22.96) | (24.72) | (15.84) | |
EV/FCF |
(23.76) | (22.92) | (24.67) | (15.80) | |
Quick Ratio |
7.43 | 9.45 | 8.70 | 0.00 | |
Current Ratio |
7.88 | 9.76 | 9.03 | 11.76 | |
Net Debt/EBITDA |
9.67 | 10.92 | 9.80 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.03 | 0.01 | 0.04 | |
Operating CF/Net income |
0.55 | 0.63 | 0.61 | 2.29 | |
Capex/Depreciation |
(1.69) | (0.61) | (1.36) | (2.64) | |
Research and Development Expense of Revenue |
120,606.25% | 1,250.30% | 1,125.99% | 205.37% | |
Selling, General and Administrative Expense of Revenue |
85,681.25% | 771.41% | 726.61% | 125.21% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
43,821.88% | 592.17% | 496.65% | 65.31% | |
Graham Net Nets |
0.14 | 0.15 | 0.14 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.93%) | (5.59%) | (6.37%) | (6.95%) | |
Free Cash Flow Yield |
(3.56%) | (3.65%) | (3.44%) | (5.00%) | |
Revenue per Share |
0.00 | 0.03 | 0.03 | 0.15 | |
Operating CF per Share |
(0.35) | (0.25) | (0.32) | (0.32) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.35) | (0.25) | (0.32) | (0.32) | |
Cash per Share |
5.38 | 5.24 | 5.15 | 0.00 | |
Shareholders Equity per Share |
5.77 | 5.47 | 5.12 | 5.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.77 | 5.47 | 5.12 | 5.08 | |
Free Cash Flow |
(40.97) | (30.64) | (39.29) | (39.95) | |
Working Capital |
589.91 | 590.62 | 586.23 | 615.01 | |
Capital Expenditures |
(0.10) | (0.04) | (0.08) | (0.18) | |
Net Current Asset Value |
589.85 | 590.62 | 586.18 | 614.96 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
3.13 | 0.01 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
6.86 | 7.09 | 5.66 | 4.13 | |
Average Assets |
816.95 | 775.53 | 759.78 | 737.21 | |
Average Common Equity |
720.47 | 721.29 | 704.96 | 679.43 |
Columns are period end dates · fundamentals updated 4 Nov 2026